Expanding Gamma Delta T Cells: Two Scalable Methods Shaping Cell Therapy

Published on Lonza Poster Presentation (CT-SP020)

Gamma delta (γδ) T cells are gaining momentum as a promising cell therapy platform due to their broad anti-tumor activity and reduced risk of graft-versus-host disease. In this Q&A, Dr. Cheng Kang Zhang of Lonza highlights two clinically scalable expansion methods using TheraPEAK® T-VIVO® Medium: zoledronic acid activation, which efficiently expands Vγ9Vδ2 cells, and anti-CD3/CD28 activation, which supports both Vδ1 and Vδ2 populations with high purity and transduction efficiency. The discussion underscores these methods' consistency across donors and potential in cancer immunotherapy.

Read the full Q&A poster on Lonza:

👉 Unlocking the potential of gamma delta T cell-based therapies (PDF)

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.